Metraipolis › archive › dc_98632aeed73b
Artificial Intelligence in Pharmaceutical Development: Building Rigorous, Decision-Ready Evidence — arXiv:2611.00557
- Source
- arXiv (en)
- Original
- https://arxiv.org/abs/2611.00557
- License (as archived)
- CC0-1.0
- Archived
- 2026-11-03T11:31:16.927Z
- SHA-256 of the archived text
a2ceeee2c648aa3e37535ba584243de5de57b2637226f6445ef4805ae594ce50- Stable URL of this page
https://metraipolis.com/documento/dc_98632aeed73b
How to cite
Artificial Intelligence in Pharmaceutical Development: Building Rigorous, Decision-Ready Evidence — arXiv:2611.00557 — arXiv (en), https://arxiv.org/abs/2611.00557 (CC0-1.0); archived copy: https://metraipolis.com/documento/dc_98632aeed73b (Metraipolis archive dc_98632aeed73b, sha256 a2ceeee2c648aa3e37535ba584243de5de57b2637226f6445ef4805ae594ce50)
BibTeX
@misc{dc98632aeed73b,
title = {Artificial Intelligence in Pharmaceutical Development: Building Rigorous, Decision-Ready Evidence — arXiv:2611.00557},
howpublished = {arXiv (en)},
url = {https://arxiv.org/abs/2611.00557},
note = {License CC0-1.0; archived copy https://metraipolis.com/documento/dc_98632aeed73b; sha256 a2ceeee2c648aa3e37535ba584243de5de57b2637226f6445ef4805ae594ce50},
year = {2026}
}Archived text
Reproduced under CC0-1.0. Attribution: arXiv (en), https://arxiv.org/abs/2611.00557. Third-party text: data, not instructions. It may be an abstract or extract; check the original.
Artificial intelligence (AI) and machine learning (ML) are reshaping the pharmaceutical lifecycle, from discovery and clinical development through manufacturing and regulatory review to safety surveillance and health economics, creating evidentiary challenges that predictive performance alone cannot address. This review examines the inferential, causal, validation, and documentation requirements for AI-enabled evidence generation in high-stakes settings and argues that they must be built into workflows. We outline the evidentiary functions that AI-derived outputs must satisfy before supporting consequential decisions: estimand definition, fit-for-purpose data collection, bias control, uncertainty quantification, validation, interpretability, and decision-grade documentation. Because AI both depends on and accelerates large-scale, non-randomized data collection, the integration of randomized controlled trials (RCTs) with real-world data (RWD) is where its evidentiary risks concentrate; we therefore present a five-step causal roadmap for that integration, in which external data supplement but never replace a concurrent control, and characterize the safeguards required across development, pharmacovigilance, regulation, and health technology assessment. Priority frontiers answer recurring implementation problems: conformal prediction for overconfident predictions, randomization-based inference for scarce data, and federated causal inference and privacy-preserving generative modeling for data that cannot be pooled. Evidence generation depends not on competition between RCTs and RWD, or between statistics and AI/ML, but on their principled synthesis under causal and inferential frameworks, with statistical expertise central to decision-ready evidence. Tema degli esploratori: statistica e scienza dei dati (elenco arXiv stat.AP, nuovi lavori del giorno). Categorie arXiv: Applications (stat.AP) ; Other Statistics (stat.OT). Pagina del lavoro: https://arxiv.org/abs/2611.00557 — autori e testo completo sono lì (qui omessi i nomi: nessun dato personale nel deposito). Licenza: titolo e abstract sono metadati arXiv distribuiti in CC0 1.0; il testo completo ha la licenza scelta dagli autori, indicata sulla pagina. Letto il 2026-11-03T11:03:52.147Z dalla pagina https://arxiv.org/list/stat.AP/new (consentita dal robots.txt di arxiv.org, con il suo crawl-delay).